| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.10. | KDventures AB: John Öhd focuses on Modus Therapeutics and continues as Senior Advisor to KDventures | 183 | GlobeNewswire (Europe) | STOCKHOLM, Sweden, October 15, 2026. KDventures AB (publ) (Nasdaq Stockholm: KDV) today announces that John Öhd is transitioning from his role as Chief Scientific Officer (CSO) to Senior Advisor at... ► Artikel lesen | |
| 14.10. | Modus Therapeutics Holding AB: Modus Therapeutics temporarily pauses enrollment in Phase IIa study of sevuparin in CKD with anemia | 179 | GlobeNewswire (Europe) | Modus Therapeutics Holding AB (publ) ("Modus" or the "Company") today announced that it has voluntarily decided, as a precautionary measure, to temporarily pause enrollment in Part 2 of the ongoing... ► Artikel lesen | |
| MODUS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 26.08. | Modus Therapeutics Holding AB: Modus Therapeutics publishes interim report for Q2 2026 | 307 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - 26 August 2026: Modus Therapeutics Holding AB ("Modus Therapeutics") hereby publishes its interim report for the second quarter of 2026. The report is available on the company's... ► Artikel lesen | |
| 28.05. | Modus Therapeutics Holding AB: Annual General Meeting in Modus Therapeutics Holding AB (publ) | 244 | GlobeNewswire (Europe) | Modus Therapeutics' Annual General Meeting on 28 May 2026 resolved in accordance with the following:
That no dividend would be paid.To discharge the board members and the managing director from liability... ► Artikel lesen | |
| 26.05. | Modus Therapeutics Holding AB: Modus Therapeutics publishes interim report for Q1 2026 | 262 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - 26 May 2026: Modus Therapeutics Holding AB ("Modus Therapeutics") hereby publishes its interim report for the first quarter of 2026. The report is available on the company's website... ► Artikel lesen | |
| 25.02. | Modus Therapeutics Holding AB: Modus Therapeutics publishes year-end report for 2025 | 869 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - 25 February 2026: Modus Therapeutics Holding AB ("Modus Therapeutics") hereby publishes year-end report for 2025. The report is available on the company's website (www.modustx.com)... ► Artikel lesen | |
| 10.12.25 | Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics initiates dosing in phase 2a study in patients with chronic kidney disease with anemia | 383 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN December 10, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has dosed the first patient in the phase 2a... ► Artikel lesen | |
| 26.11.25 | Modus Therapeutics Holding AB: Modus Therapeutics publishes Interim report for the third quarter 2025 | 592 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - 26 November 2025: Modus Therapeutics Holding AB ("Modus Therapeutics") hereby publishes an interim report for the third quarter of 2025. The report is available on the company's... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,395 | -0,71 % | NanoRepro nach starkem H1-Bericht: Diese Marke entscheidet jetzt | ||
| MARINOMED BIOTECH | 3,850 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.11.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 16.11.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.11.2026ISIN NameATMARINOMED6 MARINOMED... ► Artikel lesen | |
| REPLENISH NUTRIENTS | 0,104 | -8,77 % | Replenish Nutrients Announces Settlement from Sorbie Sharing Agreement | ||
| SANA BIOTECHNOLOGY | 1,855 | 0,00 % | Sana Biotechnology, Inc: Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates | Continued progress toward starting SC451 Phase 1/2 trial, including GLP toxicology studies, SC451 process transfer to the contract manufacturer, and clinical trial readiness Continued progress toward... ► Artikel lesen | |
| NOVABRIDGE BIOSCIENCES | 0,720 | -11,66 % | NovaBridge Biosciences: Visara Announces First Patient Dosed in ASCEND Phase 2b Trial of VIS-101 in Wet AMD | ||
| GENEURO | 0,027 | 0,00 % | NRx Pharmaceuticals, Inc.: GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS) | Invention is based on the discovery that ALS may be caused by reactivation of Human Endogenous Retrovirus K (HERV K) Envelope protein (K Env), already coded in the "dark genome" of all people. K Env... ► Artikel lesen | |
| QIAGEN | 45,200 | 0,00 % | QIAGEN N.V.: QIAGEN-Aktionäre stimmen der Berufung von Jonathan M. Pratt in die Geschäftsführung mit überwältigender Mehrheit zu | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute bekannt gegeben, dass die Aktionärinnen und Aktionäre auf einer Außerordentlichen Hauptversammlung der Berufung von Jonathan M. Pratt... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 10,500 | 0,00 % | Summit Therapeutics (SMMT) Is Losing Wall Street's Confidence | ||
| DISC MEDICINE | 77,98 | 0,00 % | Disc Medicine auf der Jefferies Global Healthcare Conference: Bitopertin auf Erholungskurs | ||
| TANGO THERAPEUTICS | 21,890 | 0,00 % | Tango Therapeutics (NDQ:TNGX): Its Pancreatic Cancer Data Was Extraordinary And Shares Have Tripled, But Are Investors Getting Ahead Of Themselves? | ||
| CG ONCOLOGY | 80,01 | +0,01 % | Truist hebt Kursziel für CG Oncology nach Studiendaten an | ||
| ERASCA | 13,780 | +0,15 % | Erasca, Bristol Myers Squibb Partner To Study Combination Therapy In Pancreatic Cancer | NEW YORK CITY (dpa-AFX) - Erasca, Inc. (ERAS) announced a clinical trial collaboration with Bristol Myers Squibb (BMY) to evaluate ERAS-0015, Erasca's investigational pan-RAS molecular glue... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,020 | +0,05 % | Beam Therapeutics auf UBS-Konferenz: Forcierte Plattformstrategie und BLA-Antrag für Sichelzelltherapie in Sicht | ||
| PRAXIS PRECISION MEDICINES | 304,85 | -0,11 % | Guggenheim hebt Kursziel für Praxis Precision Medicines auf 1.050 $ an - Kaufempfehlung bestätigt | ||
| HARMONY BIOSCIENCES | 33,110 | 0,00 % | H.C. Wainwright bekräftigt Kaufempfehlung für Harmony Bio mit Kursziel von 55 Dollar |